Pre-stroke Metformin Treatment is Neuroprotective Involving AMPK Reduction (Q39650163)

13 September 2017

title

Pre-stroke Metformin Treatment is Neuroprotective Involving AMPK Reduction (English)

1 reference

13 September 2017

1 reference

Tian Deng

1

1 reference

13 September 2017

Yan-Rong Zheng

2

1 reference

13 September 2017

Wei-Wei Hou

3

1 reference

13 September 2017

Yang Yuan

4

1 reference

13 September 2017

Zhe Shen

5

1 reference

13 September 2017

Xiao-Li Wu

6

1 reference

13 September 2017

Ying Chen

7

1 reference

13 September 2017

Li-San Zhang

8

1 reference

13 September 2017

Wei-Wei Hu

9

1 reference

13 September 2017

Zhong Chen

10

1 reference

13 September 2017

Xiang-Nan Zhang

11

1 reference

13 September 2017

publication date

27 June 2016

1 reference

13 September 2017

published in

Neurochemical Research

1 reference

13 September 2017

volume

41

1 reference

13 September 2017

issue

10

1 reference

13 September 2017

page(s)

2719-2727

1 reference

Metformin-inclusive therapy reduces the risk of stroke in patients with diabetes: a 4-year follow-up study

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

Metformin attenuates blood-brain barrier disruption in mice following middle cerebral artery occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

Pre-treatment with metformin activates Nrf2 antioxidant pathways and inhibits inflammatory responses through induction of AMPK after transient global cerebral ischemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

Improvement of functional recovery by chronic metformin treatment is associated with enhanced alternative activation of microglia/macrophages and increased angiogenesis and neurogenesis following experimental stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

Acute metformin preconditioning confers neuroprotection against focal cerebral ischaemia by pre-activation of AMPK-dependent autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

Activation of AMP-activated protein kinase by metformin protects against global cerebral ischemia in male rats: interference of AMPK/PGC-1α pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

Recommendations for standards regarding preclinical neuroprotective and restorative drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

Chronic metformin treatment improves post-stroke angiogenesis and recovery after experimental stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

Effects of Metformin in Experimental Stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

Comparative analysis of the neurovascular injury and functional outcomes in experimental stroke models in diabetic Goto-Kakizaki rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

Neuroprotective effects of adenosine monophosphate-activated protein kinase inhibition and gene deletion in stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

Cerebral ischemia-reperfusion-induced autophagy protects against neuronal injury by mitochondrial clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

Endoplasmic reticulum stress induced by tunicamycin and thapsigargin protects against transient ischemic brain injury: Involvement of PARK2-dependent mitophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

Metformin and endometrial cancer risk in Chinese women with type 2 diabetes mellitus in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

AMPK activation protects from neuronal dysfunction and vulnerability across nematode, cellular and mouse models of Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

Inhibition of G protein-coupled receptor 81 (GPR81) protects against ischemic brain injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

Dose translation from animal to human studies revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

Toxic Effects from Metformin Exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

Adult metformin ingestions reported to Texas poison control centers, 2000-2006

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

Oxygen free radicals regulate energy metabolism via AMPK pathway following cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

Cellular distribution and developmental expression of AMP-activated protein kinase isoforms in mouse central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

Preconditioning induces sustained neuroprotection by downregulation of adenosine 5'-monophosphate-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

Degradation of AMPK by a cancer-specific ubiquitin ligase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

E3 ubiquitin ligase, WWP1, interacts with AMPKα2 and down-regulates its expression in skeletal muscle C2C12 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

Downregulation of AMP-activated protein kinase by Cidea-mediated ubiquitination and degradation in brown adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

AMPK activators suppress cervical cancer cell growth through inhibition of DVL3 mediated Wnt/β-catenin signaling activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

Functional domains of the alpha1 catalytic subunit of the AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11064-016-1988-8

Evaluating the Effects of Metformin Use on Height in Children and Adolescents: A Meta-analysis of Randomized Clinical Trials

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27350579

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11064-016-1988-8

1 reference

13 September 2017

1 reference